Vijay Joish

Vijay Joish

Auto-generated profile, based on publicly available information

Vijay Joish

Lexicon Pharmaceuticals, Inc., The Woodlands, TX, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
MMMichael Morse
Michael Morse
ELEric Liu
Eric Liu
VJVijay N Joish
Vijay N Joish
LHLynn Huynh
Lynn Huynh
MCMu Cheng
Mu Cheng
DMDavid C Metz
David C Metz
Purpose: Neuroendocrine tumors (NETs) associated with carcinoid syndrome (CS) overproduce serotonin, mediated by tryptophan hydroxylase-1 (TPH1). The TPH inhibitor telotristat ethyl (TE) reduces peripheral serotonin and relieves CS symptoms. We conducted a real-world clinical practice study to explore the effects of TE on tumor growth in patients with NETs and CS. Patients and Methods: Single-arm, pre/post chart review study of patients with advanced NETs who received TE for ≥ 6 months and had ≥ 2 radiological scans within 12 months before and ≥ 1 scan after TE initiation. Linear regression and longitudinal analyses assessed changes in tumor size controlling for background NET treatment. Results: Two hundred patients were enrolled, most (61%) had well-differentiated gastrointestinal NETs (61%) and received TE for an average of 12 months (SD, 7.3). Mean reduction in tumor size after TE initiation was 0.59 cm (p=0.006). Longitudinal analysis showed an 8.5% reduction in tumor size (p=0.045) from pre- to post-TE periods. Documented NET treatment prior to initiating TE and time between scans were not significant predictors of changes in tumor size. Results were consistent in a subgroup of patients with the same documented NET treatment before and after initiating TE. Conclusion: TE may have antitumor effects consistent with serotonin overproduction in tumor growth.

1 September 2021 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
MKMatthew H Kulke
Matthew H Kulke
HKHagen F Kennecke
Hagen F Kennecke
KMKris Murali
Kris Murali
VJVijay N Joish
Vijay N Joish
Background: Inadequately controlled symptoms incur a substantial burden on patients with neuroendocrine tumors and carcinoid syndrome (CS). The effectiveness of telotristat ethyl (TE) with a somatostatin analog for uncontrolled CS diarrhea has been demonstrated in clinical trials and observational studies. TELEPRO-II was a prospective observational study evaluating TE’s effectiveness in clinical practice over the first 3 months of treatment. Methods: Patients initiating TE in 2018 participated in an optional nurse support program reporting CS symptoms during interviews at baseline and 1, 2, and 3 months after TE initiation. Eligible patients received TE for ≥ 3 months and reported symptom burden at baseline and ≥ 1 follow-up visit within the first 3 months. Daily bowel movement (BM) frequency and flushing episodes were reported as events/episodes per day. Stool consistency, nausea severity, urgency severity, and abdominal pain were reported on a severity scale (1– 10). Symptom changes were evaluated using paired-sample t-tests and Wilcoxon signed-rank tests. Analysis of symptoms based on achievement of < 30% or ≥ 30% reduction in daily BM frequency was conducted using a cumulative distribution function. Results: A total of 684/1603 (43%) patients were eligible for analysis. At baseline, patients reported a mean of 6.3 BM/day, nausea severity of 8.4/10 and stool urgency of 8.2/10. Significant improvements in all CS symptoms were observed after 3 months of TE. Mean daily BMs were reduced 64% after 3 months of TE (mean reduction [SD], – 3.99 [3.8]; P< 0.0001). Most patients (74%, n=503) reported ≥ 30% reduction in daily BM frequency; these patients also reported improvements in other symptoms (76– 87%). Patients with < 30% reduction in daily BMs also reported improvements in nausea severity (62%, n=24), daily flushing episodes (66%, n=98), abdominal pain (50%, n=60), urgency severity (38%, n=64), and stool consistency (24%, n=44). Conclusion: Patients treated with TE in a real-world setting experienced significant, clinically meaningful improvements in CS symptoms.

1 October 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
DMDavid C Metz
David C Metz
ELEric Liu
Eric Liu
VJVijay N Joish
Vijay N Joish
LHLynn Huynh
Lynn Huynh
Todor I. TotevTodor I. Totev
Todor I. Totev
MMMichael A Morse
Michael A Morse
Purpose: The TELEACE study showed reductions in tumor size in patients with neuroendocrine tumors, receiving telotristat ethyl in US clinical practice. Here, we report progression-free survival, time to tumor progression, changes in carcinoid syndrome symptoms, and indictors of overall health. Patients and Methods: This was a retrospective, single arm, pre-post medical chart review of patients with locally advanced or metastatic neuroendocrine tumors and documented carcinoid syndrome receiving telotristat ethyl for at least 6 months. Patients with poorly differentiated tumors, mixed tumor types or conflicting clinical trial enrollment were excluded. Descriptive statistics, Kaplan–Meier and chi-square tests were used to evaluate PFS, tumor progression, changes in symptoms, body weight and ECOG performance status before and after telotristat ethyl initiation. Subgroup analyses were conducted in patients with the same pre- and post-telotristat ethyl background treatment. Results: Anonymized data for 200 patients were provided by 114 physicians; patients received telotristat ethyl for a median of 9 months. Median time to tumor progression was 39.8 months (IQR, 18.7– 39.8); most had no tumor progression at 6 (92%) and 12 months (87%). Median progression-free survival was 23.7 months (17.8– 39.8); most had progression-free survival at 6 (90%) and 12 months (80%). Results were consistent in the subgroup of 65 patients with the same pre/post background treatment. Nearly all patients had improved carcinoid syndrome symptoms, stable or improved weight and ECOG performance status. Conclusion: Patients showed improvements in clinical outcomes and indicators of overall health following treatment with telotristat ethyl in this exploratory pilot study, consistent with previously observed reductions in tumor size.

1 October 2017 in Chest
Verified
Journal Article
Closed access
JCJonathan Corren
Jonathan Corren
MCMario Castro
Mario Castro
SJShyamalie Jayawardena
Shyamalie Jayawardena
VJVijay Joish
Vijay Joish
NANikhil Amin
Nikhil Amin
LELaurent Eckert
Laurent Eckert

1 May 2015 in Value in Health
Verified
Journal Article
Closed access
RHRyan Hansen
Ryan Hansen
DBD.J. Black
D.J. Black
VJV.N. Joish
V.N. Joish
MSM. Spilsbury-Cantalupo
M. Spilsbury-Cantalupo
SSS.D. Sullivan
S.D. Sullivan